Jillian Godfrey Scaife is a seasoned life sciences professional with over 15 years of management consulting experience, currently serving as the Head of the US Biosimilars Business Unit at Biogen. In this pivotal role, she leads a dynamic cross-functional team that encompasses marketing, sales, market...
Jillian Godfrey Scaife is a seasoned life sciences professional with over 15 years of management consulting experience, currently serving as the Head of the US Biosimilars Business Unit at Biogen. In this pivotal role, she leads a dynamic cross-functional team that encompasses marketing, sales, market access, franchise strategy, commercial excellence, and operations. Her expertise is instrumental in driving the launch of a multi-product ophthalmology biosimilars portfolio, as well as a significant immunology biosimilar, positioning Biogen at the forefront of the evolving biosimilars landscape.
Jillian's strategic acumen is complemented by her extensive background in global brand strategy and launch planning, where she has successfully developed and executed U.S. launch strategies that resonate with healthcare providers and patients alike. Her deep understanding of market access and reimbursement dynamics allows her to navigate complex healthcare environments, ensuring that innovative therapies reach those who need them most. By leveraging her skills in data analysis and competitive intelligence, Jillian is adept at identifying market trends and opportunities, enabling her team to make informed decisions that enhance commercial operations.
In addition to her leadership in biosimilars, Jillian's experience in oncology and molecular biology further enriches her perspective on the pharmaceutical industry. Her commitment to advancing healthcare solutions is evident in her collaborative approach, working closely with core partners to align on strategic objectives and drive operational excellence. As she continues to shape the future of biosimilars at Biogen, Jillian remains dedicated to improving patient outcomes and enhancing the accessibility of life-saving therapies.
